Download PDF
CC BY-NC-ND 4.0 · World J Nucl Med 2020; 19(01): 72-77
DOI: 10.4103/wjnm.WJNM_91_18
Case Report

Head-to-head comparison of [18F]-fluorodeoxyglucose and [18F]-fluorocholine positron emission tomography/computed tomography in three patients with rare gestational trophoblastic neoplasms: A case series

Tanyaluck Thientunyakit
1   Department of Radiology, Division of Nuclear Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand
2   NANOTEC-Mahidol University Center of Excellence in Nanotechnology for Cancer Diagnosis and Treatment, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand
,
Thonnapong Thongpraparn
1   Department of Radiology, Division of Nuclear Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand
,
Tossaporn Siriprapa
1   Department of Radiology, Division of Nuclear Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand
,
Juri G. Gelovani
3   Department of Neurosurgery, Oncology, OBGYN, Biomedical Engineering, School of Medicine, College of Engineering, and Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, USA
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

We report the efficacy of dual positron emission tomography/computed tomography (PET/CT) imaging with [18F]-2'-fluoro-2'-deoxy-D-glucose ([18F]-FDG) and [18F]-fluorocholine ([18F]-FCH) in patients with gestational trophoblastic neoplasia (GTN) for primary diagnosis and staging of this rare pregnancy-related disorder. Whole-body PET/CT with [18F]-FDG and [18F]-FCH was performed in three patients with GTN in 2 consecutive days. Each detectable lesion was characterized by visual and quantitative analyses. As compared to CT alone, PET/CT with [18F]-FDG and [18F]-FCH PET/CT revealed more hypermetabolic metastatic lesions in the body, but not in the brain. The standard uptake value of [18F]-FDG was generally higher than [18F]-FCH in all detectable tumor lesions. In conclusion, both [18F]-FDG and [18F]-FCH PET/CT can be used for diagnosis and staging for GTN, based on their sensitivity for small extracerebral metastatic lesions. Additional studies are warranted to determine whether the PET/CT imaging with [18F]-FDG and [18F]-FCH can serve as a biomarker of GTN aggressiveness, for prediction of treatment response.

Keywords

[18F]-2'-fluoro-2'-deoxy-D-glucose - [18F]-fluorocholine - choriocarcinoma - gestational trophoblastic neoplasia - positron emission tomography/computed tomography

Financial support and sponsorship

The research was partially supported by Siriraj Grant for Research Development and Faculty of Medicine Siriraj Hospital, Mahidol University, and the National Nanotechnology Center, NSTDA, Ministry of Science and Technology, Thailand, through its Center of Excellence Network program.




Publication History

Received: 23 October 2018

Accepted: 09 November 2018

Article published online:
19 April 2022

© 2020. Sociedade Brasileira de Neurocirurgia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Bandy LC, Clarke-Pearson DL, Hammond CB. Malignant potential of gestational trophoblastic disease at the extreme ages of reproductive life. Obstet Gynecol 1984;64:395-9.
  • 2 Sugarman S. Medical Oncology: A Comprehensive Review. New York: PRR; 1993. p. 243-54.
  • 3 Allen SD, Lim AK, Seckl MJ, Blunt DM, Mitchell AW. Radiology of gestational trophoblastic neoplasia. Clin Radiol 2006;61:301-13.
  • 4 Mapelli P, Mangili G, Picchio M, Gentile C, Rabaiotti E, Giorgione V, et al. Role of 18F-FDG PET in the management of gestational trophoblastic neoplasia. Eur J Nucl Med Mol Imaging 2013;40:505-13.
  • 5 Zeisel SH. Dietary choline: Biochemistry, physiology, and pharmacology. Annu Rev Nutr 1981;1:95-121.
  • 6 Yara M, Iwao B, Hara N, Yamanaka T, Uchino H, Inazu M, et al. Molecular and functional characterization of choline transporter in the human trophoblastic cell line JEG-3 cells. Placenta 2015;36:631-7.
  • 7 Celik O, Hascalik S, Sarac K, Meydanli MM, Alkan A, Mizrak B, et al. Magnetic resonance spectroscopy of premalignant and malignant endometrial disorders: A feasibility ofin vivo study. Eur J Obstet Gynecol Reprod Biol 2005;118:241-5.
  • 8 Torizuka T, Kanno T, Futatsubashi M, Okada H, Yoshikawa E, Nakamura F, et al. Imaging of gynecologic tumors: Comparison of (11) C-choline PET with (18)F-FDG PET. J Nucl Med 2003;44:1051-6.
  • 9 Huang CY, Chen CA, Hsieh CY, Cheng WF. Intracerebral hemorrhage as initial presentation of gestational choriocarcinoma: A case report and literature review. Int J Gynecol Cancer 2007;17:1166-71.